Thyroid Cancer

Oncology·MeSH: Prostatic Neoplasms

Prevalence

30.9 / 100K

Incidence

3.9 / 100K/yr

23 drugs in development·11 companies·18 clinical trials

Drug Pipeline by Phase

Approved(5)

Drug	Company
CABOMETYX	EXELIXIS, INC. (EXEL)
Cabometyx/Cometriq	Royalty Pharma plc (RPRX)
COMETRIQ	EXELIXIS, INC. (EXEL)
gavreto	RIGEL PHARMACEUTICALS INC (RIGL)
Lenvima	Merck & Co., Inc. (MRK)

Phase 3(5)

Drug	Company
cabozantinib	LOXO ONCOLOGY, INC. (LOXO)
dabrafenib	Novartis AG (NVS)
RET Inhibitor	ENANTA PHARMACEUTICALS INC (ENTA)
Trametinib	ENANTA PHARMACEUTICALS INC (ENTA)
zd6474	Sanofi (SNY)

Phase 2(4)

Drug	Company
Dabrafenib	ENANTA PHARMACEUTICALS INC (ENTA)
Dabrafenib Mesylate	ENANTA PHARMACEUTICALS INC (ENTA)
Iodine-124	UNITED THERAPEUTICS Corp (UTHR)
Selpercatinib Monotherapy	UNITED THERAPEUTICS Corp (UTHR)

Phase 1(1)

Drug	Company
nanrilkefusp alfa	IO Biotech, Inc. (IOBT)

Unknown(4)

Drug	Company
BRAF inhibitor dabrafenib and MEK inhibitor trametinib	ENANTA PHARMACEUTICALS INC (ENTA)
Cytomel	ENANTA PHARMACEUTICALS INC (ENTA)
Multitarget Tyrosine Kinase Inhibitors	ENANTA PHARMACEUTICALS INC (ENTA)
npulse vybrance percutaneous electrode system	Pulse Biosciences Inc Common Stock (DE) (PLSE)

Phase 4(4)

BioSniper tracks 23 drugs in development for Thyroid Cancer across 11 companies.

There are 18 clinical trials targeting Thyroid Cancer tracked by BioSniper.

The estimated prevalence of Thyroid Cancer is approximately 30.9 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.